The DOI matches its Crossref record.
Therapy for severe interstitial lung disease in systemic sclerosis. a retrospective study
Abstract
Objective. This retrospective observational study attempted to determine whether any of the therapies used in the management of systemic sclerosis (SSc) patients held potential benefit for patients with interstitial lung disease. Methods. All patients with SSc who had a pulmonary function test (PFT) showing a forced vital capacity (FVC) of <70% predicted and an additional PFT at least 4 months later were grouped according to the treatment they received. Changes in pulmonary function were analyzed by the mean percent predicted FVC from the initial and the final test, and by the rate of percent change in FVC (ml/year) in the first 2 years after therapy. Bronchoalveolar lavage was performed in a subset of these patients. Results. Of 363 SSc patients who had an FVC < 70% predicted, 122 had a second PFT and fulfilled the criteria for one of the following drug groups: high–dose prednisone (n = 21), immunosuppressive other than cyclophosphamide (CYC) (n = 16), CYC (n = 14), D–penicillamine (n = 37), or no drug (n = 34). In both analyses, the CYC–treated group showed significantly more improvement in FVC than did the other groups. Patients with early disease had the greatest likelihood of responding to any drug. Conclusion. This retrospective study shows that patients treated with CYC had a significant improvement in FVC over time. Prospective controlled studies of CYC treatment in early disease are necessary to determine if it can significantly alter the natural history of interstitial lung disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Cyclophosphamide versus placebo in scleroderma lung disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Goldin, J., Roth, M. D., Furst, D. E., Arriola, E., Silver, R., Strange, C., Bolster, M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055120 · Cited by 1,677
Self-citationInterstitial lung disease guideline
Wells, A. U., Hirani, N., & on behalf of the BTS Interstitial Lung Disease Guideline Group, A. S. O. T. B. T. S. S. O. C. C. (2008) · Thorax · doi:10.1136/thx.2008.101691 · Cited by 866
Hoyles, R. K., Ellis, R. W., Wellsbury, J., Lees, B., Newlands, P., Goh, N. S. L., Roberts, C., Desai, S., Herrick, A. L., McHugh, N. J., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22204 · Cited by 732
Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease
Tashkin, D. P., Elashoff, R., Clements, P. J., Roth, M. D., Furst, D. E., Silver, R. M., Goldin, J., Arriola, E., Strange, C., Bolster, M. B., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200702-326oc · Cited by 464
Self-citationInterstitial lung disease in connective tissue disorders
Fischer, A., & du Bois, R. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61079-4 · Cited by 430
White, B., Moore, W. C., Wigley, F. M., Xiao, H. Q., & Wise, R. A. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-132-12-200006200-00004 · Cited by 384
Solomon, J. J., Olson, A. L., Fischer, A., Bull, T., Brown, K. K., & Raghu, G. (2013) · European Respiratory Review · doi:10.1183/09059180.00005512 · Cited by 294
Metadata
- Authors
- Steen, V. D., Lanz, J. K., Conte, C., Owens, G. R., & Medsger, T. A.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 1994-08
- Volume
- 37
- Issue
- 9
- Pages
- 1290-1296
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2103984122
- Cited by
- 184
- References
- 0
- FWCI
- 3.17
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.